

ASX ANNOUNCEMENT MARKET RELEASE

9 May 2022

ARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP

Initial agreement includes comparison study of patient cardiac CT scans read by experts to those read by AI-based technology

- **Contracts executed to commence retrospective clinical trial in the USA**
- **Significant market entry step into the USA, which represents 42% of the global healthcare market¹**
- **Clinical Advisory Board composition completed with the appointment of Dr John (Jack) Lewin**

PERTH, AUSTRALIA., (May 9, 2022) – Artrya Limited (ASX: AYA, Artrya or the Company), creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year (www.theheartcenter.md)

Heart Center Research, LLC, a division of Huntsville Heart Center, will conduct a study to determine the efficacy of Artrya's technology. The multi-scanner retrospective study will utilise Artrya's core solution Salix Coronary Anatomy, an AI-based technology capable of analysing cardiac CT scans to report a unique combination of coronary disease biomarkers, including components of high-risk plaque.

In the study, Huntsville Heart Center researchers will utilize CT scans that were previously obtained for indicated clinical purposes. The scans will be anonymised and uploaded to cloud-based Salix, which will automatically interpret the scans using Artrya-proprietary software. The interpretation will then be compared with the interpretation of multiple expert readers.

Jory Tremblay and Ted Schwab, Co-CEO's of Artrya USA, said: "This is the Company's first clinical partnership in the U.S., and we are pleased that such a well-regarded heart centre has joined in our mission to create better detection of the world's leading killer -- heart disease.

"This clinical trial should be completed by October this year and provide validation of the technology and pave the way for its commercial use in the USA"

Artrya also today announces that Dr John (Jack) Lewin, CEO from 2006 to 2012 of the American College of Cardiology representing over 40,000 cardiologists across the United States, has joined the Artrya Clinical Advisory Board. The Clinical Advisory Board is chaired by renowned healthcare executive Dr. Jacque J. Sokolov.

¹ World Health Organisation, 2022

Investor Call

An investor call to discuss the 'Artrya Signs First U.S. Hospital Clinical Partnership' ASX Announcement and introduce the Artrya USA Inc team members, Dr Jacque Sokolov, Chairman & President, and Co-CEOs Jory Tremblay and Ted Schwab will be held **11am AEDT (9am AWST) on Tuesday, 10 May 2022..**

Join the conference call on Zoom by [clicking here](#).

This announcement was approved by the Artrya Board.

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

Artrya USA Inc. is a wholly-owned subsidiary of Artrya Limited.

For more information: www.artrya.com.

For further investor enquiries please contact:

John Barrington
Artrya Limited
0419 850 502
investors@artrya.com